Sign In
Buy APLT
$0.0959
+0 (+0%)
At Close: Apr 28, 2026
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
12:56pm, Thursday, 19'th Sep 2024
Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer
09:16am, Thursday, 19'th Sep 2024
Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits in g
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
03:09pm, Wednesday, 18'th Sep 2024
FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th
Why Applied Therapeutics Stock Is Skyrocketing Today
10:56am, Wednesday, 18'th Sep 2024
The FDA won't hold an Advisory Committee meeting to review Applied Therapeutics' regulatory filing for govorestat. This move could increase the likelihood that the drug will win FDA approval.
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
02:37pm, Wednesday, 31'st Jul 2024
William Blair initiated coverage on Applied Therapeutics Inc. APLT, a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.
Applied Therapeutics Added to Russell 3000® Index
07:00am, Monday, 01'st Jul 2024
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molec
Top 4 Health Care Stocks That May Keep You Up At Night This Month
08:44am, Tuesday, 11'th Jun 2024
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia
03:19am, Wednesday, 29'th May 2024
Applied Therapeutics is a clinical-stage biotech focused on treating symptoms of galactosemia in the central nervous system. Govorestat (AT-007) is in late-stage regulatory approval for galactosemia,
Applied Therapeutics Reports First Quarter 2024 Financial Results
07:00am, Thursday, 09'th May 2024
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates agai
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
07:00am, Monday, 15'th Apr 2024
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated mole
US FDA extends review of Applied Therapeutics' genetic disease drug
04:52pm, Thursday, 28'th Mar 2024
The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday.
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
04:30pm, Thursday, 28'th Mar 2024
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated mole
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
10:26am, Wednesday, 13'th Mar 2024
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
07:00am, Wednesday, 06'th Mar 2024
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates ag
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
09:48am, Wednesday, 28'th Feb 2024
Applied Therapeutics (NASDAQ: APLT ) stock is on the rise Wednesday after the clinical-stage biopharmaceutical company got an update from the Food and Drug Administration (FDA). The FDA has accepted t
